Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Matrix metalloproteinases (MMPs), specifically MMP-2 and MMP-9, were previously linked to worse survival in gastric cancer patients.
• Further investigation is needed to validate these findings and explore other MMPs and their inhibitors in gastric cancer prognosis.

Purpose of the Study:

• To re-evaluate the prognostic significance of MMP-2 and MMP-9 in a larger gastric cancer cohort using updated methodologies.
• To assess the roles of MMP-7, MMP-8, TIMP-1, and TIMP-2 in gastric cancer and their correlation with clinicopathological parameters and patient survival.

Main Methods:

• Quantification of MMP-2, MMP-9, MMP-7, MMP-8, TIMP-1, and TIMP-2 in tumor and normal gastric tissues from 81 patients.
• Utilized enzyme-linked immunosorbent assay (ELISA) and bioactivity assays for MMP determination.
• Correlated MMP and TIMP levels with clinicopathological parameters (TNM, WHO, Laurén classification) and patient survival data.

Main Results:

• All assessed MMPs (MMP-2, MMP-7, MMP-8, MMP-9) and TIMP-1 were significantly elevated in gastric tumor tissues compared to normal mucosa.
• MMP-7, MMP-8, MMP-9, TIMP-1, and TIMP-2 levels showed some correlations with clinicopathological features but were not significantly associated with patient survival.
• Elevated MMP-2 levels in tumors were confirmed as an independent prognostic factor for gastric cancer, irrespective of the assay method used.

Conclusions:

• While several MMPs and TIMPs are upregulated in gastric cancer and correlate with some clinicopathological parameters, only MMP-2 demonstrates independent prognostic value for patient survival.
• This study reinforces the importance of MMP-2 as a biomarker for predicting outcomes in gastric cancer.
• Further research may elucidate the precise mechanisms by which MMP-2 influences gastric cancer progression and survival.